SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/251718"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/251718" > Outcomes in patient...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004617naa a2200637 4500
001oai:gup.ub.gu.se/251718
003SwePub
008240528s2016 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/2517182 URI
0247 a https://doi.org/10.1093/ndt/gfw0472 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Galle, J. C.4 aut
2451 0a Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
264 c 2016-04-15
264 1b Oxford University Press (OUP),c 2016
338 a electronic2 rdacarrier
520 a Background. Extended dosing of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) once biweekly or monthly reduces anaemia treatment burden. This observational study assessed outcomes and dosing patterns in patients with chronic kidney disease not on dialysis (CKD-NoD) commencing extended dosing of DA. Methods. Adult CKD-NoD patients starting extended dosing of DA in Europe or Australia in June 2006 or later were followed up until December 2012. Outcomes included haemoglobin (Hb) concentration, ESA dosing, mortality rates and receipt of dialysis and renal transplantation. Subgroup analyses were conducted for selected outcomes. Results. Of 6035 enrolled subjects, 5723 (94.8%) met analysis criteria; 1795 (29.7%) received dialysis and 238 (3.9%) underwent renal transplantation. Mean (standard deviation) Hb concentration at commencement of extended dosing was 11.0 (1.5) g/dL. Mean [95% confidence interval (CI)] Hb 12 months after commencement of extended dosing (primary outcome) was 11.6 g/dL (11.5, 11.6) overall and was similar across countries, with no differences between subjects previously treated with an ESA versus ESA-naive subjects, subjects with versus without prior renal transplant or diabetics versus non-diabetics. Weekly ESA dose gradually decreased following commencement of extended DA dosing and was similar across subgroups. The decrease in weekly DA dose was accompanied by an increase in the proportion of patients receiving iron therapy. Hb concentrations declined following changes in ESA labels and treatment guidelines. The mortality rate (95% CI) was 7.06 (6.68, 7.46) deaths per 100 years of follow-up. Subjects alive at study end had stable Hb concentrations in the preceding year, while those who died had lower and declining Hb concentrations in their last year. Conclusions. Long-term, extended dosing of DA maintained Hb concentrations in patients already treated with an ESA and corrected and maintained Hb in ESA-naive patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a anaemia
653 a chronic kidney disease
653 a darbepoetin alfa
653 a erythropoiesis-stimulating agent
653 a extended dosing
653 a ERYTHROPOIESIS-STIMULATING AGENTS
653 a POSITION STATEMENT
653 a HEMOGLOBIN
653 a CONCENTRATIONS
653 a ANEMIA MANAGEMENT
653 a PRACTICE ERBP
653 a DE-NOVO
653 a EVERY
653 a VARIABILITY
653 a MORTALITY
653 a LEVEL
7001 a Addison, J.4 aut
7001 a Suranyi, M. G.4 aut
7001 a Claes, K.4 aut
7001 a Di Giulio, S.4 aut
7001 a Guerin, A.4 aut
7001 a Herlitz, Hans,d 1946u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xherha
7001 a Kiss, I.4 aut
7001 a Farouk, M.4 aut
7001 a Manamley, N.4 aut
7001 a Wirnsberger, G.4 aut
7001 a Winearls, C.4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org
7730 t Nephrology Dialysis Transplantationd : Oxford University Press (OUP)g 31:12, s. 2073-2085q 31:12<2073-2085x 0931-0509x 1460-2385
8564 u https://gup.ub.gu.se/publication/251718x primaryx freey FULLTEXT
8564 u https://academic.oup.com/ndt/article-pdf/31/12/2073/17109369/gfw047.pdf
8564 8u https://gup.ub.gu.se/publication/251718
8564 8u https://doi.org/10.1093/ndt/gfw047

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy